T1	Participants 0 132	Clofarabine Â± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
T2	Participants 2164 2254	Forty-one patients had active leukemia at the time of transplant, and 35 achieved CR (85%)
T3	Participants 1487 1656	Nine patients had chronic myeloid leukemia (CML) (BC: 2, second AP: 3, and tyrosine-kinase inhibitor refractory first chronic phase [CP]: 4). Forty-two patients had AML:
